☆ 4.7 Article

Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Medicine, Research & Experimental

Hepatocellular Carcinoma Immunotherapy

Rubens Copia Sperandio et al.

Summary: Hepatocellular carcinoma (HCC) is a common primary liver malignancy and a leading cause of cancer-related death. Single-agent anti-PD-1 immune checkpoint inhibitors (ICIs) showed initial promise, but failed to demonstrate efficacy in phase III trials. The combination of atezolizumab and bevacizumab has been approved as first-line therapy, showing significant improvements in response rate, progression-free survival, and overall survival compared to standard treatments. Ongoing clinical trials are evaluating the use of ICIs in combination with other drugs.

ANNUAL REVIEW OF MEDICINE (2022)

添加到收藏夹

Article Oncology

A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study

Christine M. Bestvina et al.

Summary: A randomized phase 1 trial combined nivolumab and ipilimumab with sequential or concurrent multisite SBRT in patients with stage IV NSCLC to evaluate safety and obtain preliminary activity data. Results showed that concurrent therapy was not more toxic than sequential therapy, and multisite SBRT was well tolerated in widely metastatic patients. Multimodality therapy resulted in durable metastasis control and encouraging early overall survival.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

Ahmed Omar Kaseb et al.

Summary: This study aimed to evaluate the safety and tolerability of perioperative immunotherapy in patients with resectable hepatocellular carcinoma. The findings suggest that nivolumab alone or in combination with ipilimumab is safe and feasible in this patient population, supporting further studies of immunotherapy in the perioperative setting for hepatocellular carcinoma.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma

Chang Gon Kim et al.

Summary: HPD can occur in a fraction of HCC patients treated with PD-1 inhibitors, leading to worse survival outcomes and missed treatment opportunities for the majority of affected patients. Analyzing baseline immune profiles and tumor growth dynamics during treatment could help identify HPD earlier for optimal patient management.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Oncology

Combined Stereotactic Body Radiotherapy and Immunotherapy (SBRT-IO) vs. TACE in Locally Advanced Hepatocellular Carcinoma (HCC): Propensity Score Matching Analysis

C.L. Chiang et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study

Riad Salem et al.

Summary: The LEGACY study evaluated the efficacy of yttrium-90 glass microspheres in treating solitary, unresectable HCC <= 8 cm, showing promising response rates and durable responses in a multicenter setting.

HEPATOLOGY (2021)

添加到收藏夹

Review Oncology

Integration of Systemic and Liver-Directed Therapies for Locally Advanced Hepatocellular Cancer: Harnessing Potential Synergy for New Therapeutic Horizons

Eric H. Bent et al.

Summary: Treatment options for locally advanced hepatocellular carcinoma (HCC) have evolved significantly in recent years, with the approval of multiple systemic therapies and advancements in locoregional therapy. There is a growing interest in rationally designed combination therapies for patients with unresectable HCC, given their poor prognosis. This article reviews the available treatment options and discusses the rationale, ongoing trials, and future prospects for combining locoregional and systemic therapy in both definitive and neoadjuvant settings.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial

Jason J. Luke et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Review Immunology

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond

Yun Hua Lee et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Oncology

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial

Thomas Yau et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives

Piera Federico et al.

CANCERS (2020)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

M. D. Hellmann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Oncology

Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy

Chi-Leung Chiang et al.

FRONTIERS IN ONCOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Jorge A. Marrero et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Oncology

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

Jason J. Luke et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Peter R. Galle et al.

JOURNAL OF HEPATOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

添加到收藏夹

Article Oncology

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

R. J. Motzer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Oncology

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies

Stephanie K. Schaub et al.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2018)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry et al.

LANCET (2017)

添加到收藏夹

Review Oncology

Radiotherapy and immunotherapy: a beneficial liaison?

Ralph R. Weichselbaum et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. D. Wolchok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Oncology

Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome analysis in 185 patients

Naoko Sanuki et al.

ACTA ONCOLOGICA (2014)

添加到收藏夹

Article Gastroenterology & Hepatology

Immunodominance and Functional Alterations of Tumor-Associated Antigen-Specific CD8+ T-Cell Responses in Hepatocellular Carcinoma

Tobias Flecken et al.

HEPATOLOGY (2014)

添加到收藏夹

Article Oncology

Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma

Alexis Bujold et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Role of surgical resection for multiple hepatocellular carcinomas

Sung Hoon Choi et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2013)

添加到收藏夹

Article Oncology

STEREOTACTIC BODY RADIOTHERAPY FOR PRIMARY HEPATOCELLULAR CARCINOMA

David L. Andolino et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)

添加到收藏夹

Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.